Post-Hemorrhagic Anemia Treatment Market Size

  • Report ID: 3784
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Post-Hemorrhagic Anemia Treatment Market Size

Post-Hemorrhagic Anemia Treatment Market size was over USD 5.61 billion in 2024 and is anticipated to cross USD 11.82 billion by 2037, witnessing more than 5.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of post-hemorrhagic anemia treatment is estimated at USD 6.15 billion.

The growth of the market can be attributed to the higher cases of road accidents and trauma. Sudden accidents can cause severe injuries that leads to heavy blood loss. Around the world, 1.35 million people die due to road accident every year. Nearly 3,700 people per day die worldwide in collisions involving automobiles, buses, motorbikes, bicycles, lorries, or pedestrians.

In addition to these, factors that are believed to fuel the market growth of post-hemorrhagic anemia treatment include the growing number of trauma cases across the globe, and increasing prevalence of bleeding disorders, such as hemophilia and Von Willebrand disease. In 2020, approximately 210,000 people in the world suffered from hemophilia, and about 84,000 were diagnosed with Von Willebrand disease. Along with these, rise in awareness levels regarding anemia, and escalating technological developments in the pharmaceutical sector, especially in developed and developing nations. Furthermore, surge in the percentage of population with a family history of anemia and blood diseases is projected to elevate the total number of cases of acute post-hemorrhagic anemia. This in turn is predicted to offer abundant growth opportunities to the market in the near future.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3784
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of post-hemorrhagic anemia treatment is estimated at USD 6.15 billion.

The post-hemorrhagic anemia treatment market size was valued at USD 5.3 Billion in 2023 and is anticipated to exceed USD 11.16 Billion by the end of 2036, registering over 5.9% CAGR during the forecast period i.e., between 2024-2036. Growing number of trauma cases across the globe, and increasing prevalence of bleeding disorders. are the major factors driving the market growth.

North America industry is poised to dominate majority revenue share of 36% by 2037, attributed to high number of hospital admissions, and rising government focus to improve healthcare infrastructure in the region.

The major players in the market are Rockwell Medical, Inc., Amgen Inc., Vifor Pharma Management Ltd., F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., AMAG Pharmaceuticals, Akebia Therapeutics
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample